Technology | 2016.09.14
Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016
PARIS, September 14, 2016 /PRNewswire/ -- Identification of Novel Molecular Mechanisms of Action of MD1003 in Neurodegeneration MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces that new preclinical data in adrenoleukodystrophy...
For more information, please visit
http://www.prnewswire.com/news-releases/[...]-sclerosis-2016-593358731.html
